Tissue Regenix Group PLC Posting of Annual Report and Notice of AGM (3166M)
April 27 2018 - 2:01AM
UK Regulatory
TIDMTRX
RNS Number : 3166M
Tissue Regenix Group PLC
27 April 2018
Tissue Regenix Group plc
Posting of Annual Report and Notice of AGM
Leeds, 27 April 2018 - Tissue Regenix Group (AIM:TRX) ("Tissue
Regenix" or "The Group") the regenerative medical devices company
announces that the Annual Report and Accounts for the year ended 31
December 2017, the Notice of Annual General Meeting ("AGM") and the
Form of Proxy have been sent to Shareholders. These documents are
also available on the Company's website, www.tissueregenix.com
Tissue Regenix Group AGM will be held at 10:00am on 24 May 2018
at the offices of DLA Piper UK LLP, Princes Exchange, Princes
Street, Leeds, LS1 4BY.
For more Information:
Tissue Regenix Group plc Tel: 0330 430 3073 /
Caitlin Pearson Head of Communications 07920272 441
----------------------------------------- ---------------------
Jefferies International Ltd Tel: 020 7029 8000
Simon Hardy / Christopher Binks
----------------------------------------- ---------------------
FTI Consulting Tel: 0203 727 1000
Brett Pollard / Mo Noonan/ Mary Whittow
========================================= =====================
About Tissue Regenix
Tissue Regenix is a leading medical devices company in the field
of regenerative medicine. Tissue Regenix was formed in 2006 when it
was spun-out from the University of Leeds, UK. The company's
patented decellularisation ('dCELL(R) ') technology removes DNA and
other cellular material from animal and human soft tissue leaving
an acellular tissue scaffold which is not rejected by the patient's
body and can then be used to repair diseased or worn out body
parts. Current applications address many critical clinical needs
such as sports medicine, heart valve replacement and wound
care.
In November 2012 Tissue Regenix Group plc set up a subsidiary
company in the United States - 'Tissue Regenix Wound Care Inc.',
January 2016 saw the establishment of joint venture GBM-V, a multi-
tissue bank based in Rostock, Germany.
In August 2017 Tissue Regenix acquired CellRight Technologies(R)
, a biotech company that specializes in regenerative medicine and
is dedicated to the development of innovative osteoinductive and
wound care scaffolds that enhance healing opportunities of defects
created by trauma and disease. CellRight's human osteobiologics may
be used in spine, trauma, general orthopedic, foot & ankle,
dental, and sports medicine surgical procedures.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NOAFKADQCBKDBQB
(END) Dow Jones Newswires
April 27, 2018 02:01 ET (06:01 GMT)
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From May 2024 to Jun 2024
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From Jun 2023 to Jun 2024